How Research Peptides Are Made: From API to Filled Vial
Every lyophilized research peptide goes through the same basic journey. The peptide itself — the API — is built one amino acid at a time and purified. It is then dissolved and filtered, filled into glass vials, freeze-dried into a solid cake, sealed and documented. This guide walks through each stage of how peptides are made, the way it is generally done across the industry, with links to the primary sources and three short videos.
How peptides are made, step by step
The eight steps below cover the whole path. Steps 1–3 make the API. Steps 4–7 are the “fill-finish” stage that turns bulk API into individual vials. Step 8 ties the lot together on paper. Note that, for freeze-dried vials, filling comes before the vial is lyophilized: the liquid goes into the vial first and is dried in place.[6]
- 1
Build the chain
Solid-phase peptide synthesis adds one protected amino acid at a time to a resin bead, then cleaves the finished chain off.
Read more → - 2
Purify
Preparative reversed-phase HPLC separates the target peptide from truncated and side-product sequences.
Read more → - 3
Exchange, dry & test
The counter-ion may be exchanged, the purified peptide is freeze-dried to a bulk powder, and the API lot is tested.
Read more → - 4
Compound & filter
The API is dissolved into a bulk solution and, in sterile manufacturing, passed through a 0.2–0.22 µm sterilizing-grade filter.
Read more → - 5
Fill & part-stopper
Measured volumes go into clean glass vials; stoppers are set partway so vapor can escape during drying.
Read more → - 6
Freeze-dry in the vial
Freezing, primary drying (sublimation) and secondary drying leave a dry “cake”.
Read more → - 7
Stopper, crimp & inspect
Stoppers are pressed home inside the dryer, aluminum seals are crimped on, and vials are inspected.
Read more → - 8
Document the lot
Test results for the lot are recorded on a certificate of analysis tied to the lot number on the label.
Read more →
What “API” means
API stands for active pharmaceutical ingredient. For a research peptide, it is the purified peptide itself, before it is divided into vials — the term manufacturers and regulators use for the substance at the center of a product. Anything else in a finished vial, such as counter-ions or residual water, is not the API, which is one reason a certificate of analysis can report both purity and net peptide content.
For USAPI products, the sourcing statement is simple: API sourced from an FDA-registered facility in the United States, documented on every lot’s COA. That is the only sourcing claim we make, and it is documented on every lot’s COA.
Making the API: solid-phase peptide synthesis
Building the chain on a bead
Almost all synthetic peptides today are made by solid-phase peptide synthesis (SPPS). R. Bruce Merrifield introduced the method in 1963 and received the 1984 Nobel Prize in Chemistry for it.[1][2] The idea is to anchor the first amino acid to an insoluble resin bead and build the chain while it stays attached, so excess reagents and by-products can simply be washed away after each step instead of purifying the product every time.[2][3]
In the most widely used approach, Fmoc/tBu chemistry, every incoming amino acid arrives with its reactive amine capped by a temporary Fmoc protecting group and its side chain capped by an acid-removable group.[3] The chain grows through a repeating cycle:
- Deprotection. A mild base, typically piperidine, removes the Fmoc group to expose the amine at the end of the chain.[3]
- Washing. Solvent washes clear away the base and by-products.
- Coupling. The next Fmoc-protected amino acid is activated and forms a peptide bond with the exposed amine.[3]
- Washing again, then the cycle repeats, one residue at a time, until the full sequence is assembled. Automated synthesizers run these cycles unattended.
Cleavage. When the chain is complete, a strong acid cocktail based on trifluoroacetic acid (TFA), with “scavengers” to trap reactive fragments, cuts the peptide off the resin and removes the side-chain protecting groups in one step.[3] The product is precipitated, washed and dried. At this point it is a crude peptide: the target sequence mixed with truncated chains, deletion sequences and other related impurities that purification must remove.[3][4]
Purification by preparative RP-HPLC
The crude peptide is purified, most often by preparative reversed-phase high-performance liquid chromatography (RP-HPLC). The mixture is pushed through a column packed with a hydrophobic material; different molecules stick and release at different rates, so the target peptide comes off at a characteristic retention time, separated from close-related impurities.[4] Fractions are collected, checked, pooled and concentrated. RP-HPLC is also the analytical method later used to measure purity on the COA.[4]
Counter-ion exchange: TFA vs acetate
Because TFA is used in cleavage and in common HPLC mobile phases, a freshly purified peptide usually ends up as a TFA salt. Many basic residues in the peptide pair with a counter-ion. Some producers run an extra ion-exchange step to swap TFA for another counter-ion, commonly acetate.[5] The choice of counter-ion affects the powder’s weight and properties, which is part of why net peptide content is reported separately from HPLC purity.[5]
Release testing of the API
Before it is used, an API lot is tested against a written specification. A typical analytical panel includes:
Purity by HPLC
The percentage of the peptide-related signal that is the target peptide. USAPI products carry a ≥99% HPLC purity specification.
Identity by mass spec
Mass spectrometry (often LC-MS) confirms the measured mass matches the expected molecular weight of the sequence.
Net peptide content
How much of the powder’s weight is actually peptide, as opposed to counter-ions and water.
Water & counter-ion
Water content (often by Karl Fischer titration) and, where relevant, residual solvents and counter-ion level.
Appearance & related data
Visual appearance, and depending on the material, heavy metals or other attributes a specification calls for.
The exact panel varies by material and by the specification in force. Our guide to reading a COA walks through what each line means.
Lyophilization (freeze-drying)
Lyophilization, or freeze-drying, removes most of the water from a frozen product by subliming ice directly to vapor under vacuum, at low temperature. For many peptides that are more stable dry than in solution, this is how a stable, shippable solid is produced. FDA’s inspection guide describes freeze-drying as a process in which the solvent is frozen and then removed by sublimation in a vacuum.[6] It runs in three stages:
1. Freezing
The filled vials are cooled until the solution is fully frozen. How the material freezes sets the ice-crystal structure, which in turn shapes the pores the vapor will later escape through, and the look of the final cake.[6][7]
What remains is the cake: the dry, porous solid left in the vial. Its appearance can range from a firm puck to a loose powder, and a collapsed or shrunken cake can be a sign the cycle ran too warm.[6] Low residual moisture matters because leftover water can drive changes on storage; moisture is one of the attributes checked on release.[6][7]
Filling: from bulk solution to sealed vial
For a freeze-dried product, filling happens before lyophilization. The general fill-finish sequence is:
- Compounding the bulk solution. The API is dissolved in water (and any formulation components) to a target concentration, so each vial will receive a known amount.
- Sterile filtration. For products meant to be sterile, the solution is passed through a sterilizing-grade membrane filter, commonly rated 0.2–0.22 µm, to remove microorganisms. Aseptic processing relies on this step because the solution cannot be sterilized by heat later.[8]
- Aseptic filling. Measured volumes are dispensed into clean, depyrogenated glass vials in a tightly controlled environment.[8]
- Part-stoppering. Special lyophilization stoppers are set partway into the neck, leaving a vent so water vapor can escape during drying.[6]
- Stoppering and crimp-capping. After drying, the stoppers are pushed fully home inside the dryer, then an aluminum crimp seal is pressed over the stopper to hold the closure.[6][8]
Why Type I borosilicate glass, and why 5 mL
The container is part of the product. USAPI uses full-size 5 mL Type I borosilicate glass vials, uncoated and with no plastic liner. Type I is the pharmacopeia’s highest glass class for hydrolytic resistance, it resists thermal shock during the freeze-and-vacuum cycle, and it is a tight barrier to moisture and gases. A full-size vial also leaves generous headspace above the cake. Our dedicated article, why we use 5 mL Type I borosilicate glass vials, covers the glass classes and the sources in detail.
Sterilization: terminal vs aseptic
There are two broad routes to a sterile product, and the difference matters for peptides.
| Approach | How it works | Fit for peptides |
|---|---|---|
| Terminal sterilization | The product is sealed in its final container, then sterilized — most often by moist heat (autoclave). It is the preferred method where the product can take it.[8] | Usually unsuitable: heat can degrade peptides. |
| Aseptic processing | The solution is sterilized by filtration, then filled and sealed under conditions designed to keep it sterile, because it cannot be sterilized afterward.[8] | The common route for heat-sensitive materials such as peptides. |
FDA guidance notes that a product sterilized by terminal processes offers a higher degree of sterility assurance than one made aseptically, and that aseptic processing is used where terminal sterilization is not feasible.[8]
Because aseptic processing has no final sterilizing step, the environment does the work. In general this means:
- Sterile filtration of the bulk solution through a 0.2–0.22 µm sterilizing-grade filter.[8]
- Cleanroom classification. Critical filling happens in the cleanest air class — ISO 5, equivalent to EU GMP Grade A — with progressively less strict classes in the surrounding rooms. ISO 14644-1 defines these air-cleanliness classes by particle count.[9][10]
- Environmental monitoring of air, surfaces and personnel for particles and microorganisms during production.[8][10]
- Container–closure integrity. The sealed vial must stay a barrier to microorganisms, so closure systems are designed and tested to keep the contents protected.[8]
How lot documentation ties it together
All of the above only means something if you can trace it. That is the job of the certificate of analysis (COA). Each lot is tested, and the results — purity, identity, test date and more — are recorded on a COA keyed to the lot number printed on the vial label.
On USAPI products, every vial carries a lot number you can check. Enter it in the lot lookup on our COA / Lab Results page to pull up the matching certificate, and use our guide to reading a COA to interpret it. This is what connects a finished, freeze-dried vial back to the API it was made from. API sourced from an FDA-registered facility in the United States, documented on every lot’s COA.
Frequently asked questions
Is a lyophilized peptide the same thing as the API?
Not quite. The API (active pharmaceutical ingredient) is the purified peptide itself, usually stored as a bulk freeze-dried powder after purification. A lyophilized vial is a finished unit: an API solution that has been filled into a vial, freeze-dried in that vial into a cake, then stoppered and sealed.
Why are research peptides supplied as a freeze-dried powder?
Many peptides are much less stable in water than in the dry state. Lyophilization removes most of the water at low temperature, which in general slows the chemical and physical changes that happen in solution and gives a solid that is easier to store and ship.
How is HPLC purity different from net peptide content?
HPLC purity is the share of the peptide-related signal on a chromatogram that belongs to the target peptide. Net peptide content is how much of the powder’s total weight is peptide, as opposed to counter-ions such as acetate or TFA and residual water. A lot can be 99% pure by HPLC and still be well under 100% peptide by weight. Our COA guide explains both.
Can peptides be heat-sterilized?
In general, no. Terminal sterilization with moist heat (autoclaving) is the preferred method for products that can withstand it, but heat can degrade peptides. That is why sterile peptide products are typically made by sterile filtration and aseptic processing instead.
What is the difference between TFA and acetate salts?
TFA (trifluoroacetic acid) is used to cleave peptides from the resin and in HPLC mobile phases, so purified peptides often end up as TFA salts. Some manufacturers then exchange TFA for another counter-ion such as acetate. The counter-ion is part of the powder’s weight, which is one reason net peptide content is below 100%.
Does this page describe how USAPI products are made?
No. It describes general industry practice. What we state about USAPI products is limited to what is documented: a ≥99% HPLC purity specification, full-size 5 mL Type I borosilicate glass vials, a lot-level COA for every lot, and shipping from the USA. API sourced from an FDA-registered facility in the United States, documented on every lot’s COA. All USAPI products are for research use only.
Where do I find the documentation for my lot?
Every USAPI vial label carries a lot number. Enter it in the lot lookup on our COA page to find the matching certificate of analysis.
Sources & references
Every factual claim about industry practice on this page is tied to a source below. These are official guidance documents, pharmacopeia-related references and peer-reviewed literature. They did not use USAPI products, and no claims are made about USAPI products on the basis of this literature.
- 1 The Nobel Prize in Chemistry 1984: Press release. Awarded to R. Bruce Merrifield “for his development of methodology for chemical synthesis on a solid matrix.” NobelPrize.org. NobelPrize.org.
- 2 Merrifield RB. Solid Phase Synthesis. Nobel Lecture, December 8, 1984. Nobel lecture (PDF).
- 3 Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science. 2016;22(1):4–27. doi:10.1002/psc.2836. Full text (PMC).
- 4 Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007;386:3–55. doi:10.1007/978-1-59745-430-8_1. Full text (PMC).
- 5 Sikora K, Jaśkiewicz M, Neubauer D, Migóń D, Kamysz W. The Role of Counter-Ions in Peptides—An Overview. Pharmaceuticals. 2020;13(12):442. doi:10.3390/ph13120442. Full text (PMC).
- 6 U.S. Food and Drug Administration. Guide to Inspections: Lyophilization of Parenteral (7/93). FDA inspection guide.
- 7 Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharmaceutical Research. 2004;21(2):191–200. doi:10.1023/B:PHAM.0000016234.73023.75. doi:10.1023/B:PHAM.0000016234.73023.75.
- 8 U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. September 2004. FDA guidance.
- 9 European Commission. EudraLex Volume 4, EU GMP Guidelines, Annex 1: Manufacture of Sterile Medicinal Products. August 2022. Annex 1 (PDF).
- 10 International Organization for Standardization. ISO 14644-1:2015. Cleanrooms and associated controlled environments — Part 1: Classification of air cleanliness by particle concentration. ISO catalogue page.
- 11 U.S. Food and Drug Administration. Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers. June 2012. FDA guidance.
Keep reading
This article is general reference for laboratory research. Related pages: the Glossary of research terms, COA / Lab Results and the Research Library. You can also browse the catalog. All USAPI products are for research use only and are not for human or veterinary use.